Amgen receives US FDA approval for Uplizna to treat Adults with generalized myasthenia gravis: Thousand Oaks, California Saturday, December 13, 2025, 11:00 Hrs [IST] Amgen announc ...

Amid a swell of regulatory successes in the myasthenia gravis arena this decade, Amgen is wading into the fray with a new indication for its monoclonal antibody Uplizna. Thursday, the FDA greenlighted ...

Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved UPLIZNA® (inebilizumab-cdon) for the treatment of generalized myasthenia gravis (gMG) in adults who ...

At the 2025 AANEM Annual Meeting, groundbreaking research was presented that advances the understanding and management of myasthenia gravis (MG), reports Dr Katherine Ruzhansky. One study identified ...

A new study from Mayo Clinic underscores the widespread impact of menopause symptoms on midlife women—and raises concern that most are navigating this stage of life without medical care to help manage ...

Generalized myasthenia gravis (gMG) affects most patients through a handful of well-characterized neuromuscular junction autoantibodies, but a wide range of differences among patients affect the ...

A new retrospective analysis compared clinical features of White, Hispanic, and African-American patients with MG who visited a single university-based clinic. After adjusting for covariates, the ...

Albert Stowell's family thought he was having a stroke. It was Easter dinner 2014, and they were all gathered around the table when he started slurring his words. A trip to the emergency room and a CT ...

Treatment with cemdisiran was associated with a statistically significant improvement in MG-ADL total score compared with placebo. Topline results were announced from a phase 3 trial evaluating ...

Regeneron has reported a phase 3 win in generalized myasthenia gravis (gMG), positioning the pharma to file for FDA approval of its siRNA candidate in the increasingly competitive neuromuscular ...